Results 1 to 10 of about 775,670 (354)

Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management

Nature Reviews Clinical Oncology, 2022
Lecia V Sequist, Jessica J Lin
exaly   +2 more sources

EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)—A Podcast Discussion Between Patients and Oncologists

Oncology and Therapy, 2023
This podcast, for healthcare professionals (HCPs), patients, and patient advocates, is a discussion among a panel of two patients (and co-founders of the patient advocacy group EGFR Resisters, https://egfrcancer.org/ ) and two oncologists.
Stephen V. Liu, Ivy B. Elkins, Jill Feldman, Sarah B. Goldberg   +3 more
doaj   +1 more source

Antiproliferative Activity of Lignans from Olea ferruginea: In Vitro Evidence Supported by Docking Studies

Frontiers in Bioscience-Landmark, 2023
Background: The aim of the current study was to investigate the anticancer potential of bioactive compounds isolated from the leaves of Olea ferruginea (O. ferruginea). Lignans from O.
Abdur Rauf, Umer Rashid, Aniqa Atta, Ishaq Khan, Zafar Ali Shah, Bushra Mobeen, Aneela Javed, Taghrid S. Alomar, Najla Almasoud, Saima Naz, Zubair Ahmad, Giovanni Ribaudo   +11 more
doaj   +1 more source

To evaluate the expression of EGFR and Ki-67 markers in oral squamous cell carcinoma and find its association with grading and staging of tumors

Journal of Dr. NTR University of Health Sciences, 2023
Background: In this study, we assessed the immunohistochemical expression of EGFR and Ki-67 in cases of oral squamous cell carcinoma and its association with grading and staging.
Sayali Gadre, Amit V. Varma, Garima Malpani, Kamal Malukani, Seema Jindal, Veena Verma   +5 more
doaj   +1 more source

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

Journal of Clinical Oncology, 2021
PURPOSE Non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved tyrosine kinase inhibitors.
Keunchil Park, E. Haura, N. Leighl, P. Mitchell, C. Shu, N. Girard, S. Viteri, Ji-Youn Han, Sang-We Kim, C. Lee, J. Sabari, A. Spira, Tsung-Ying Yang, Dong-Wan Kim, K. Lee, R. Sanborn, J. Trigo, K. Goto, Jong-Seok Lee, J. Yang, R. Govindan, J. Bauml, P. Garrido, M. Krebs, K. Reckamp, John Xie, J. Curtin, N. Haddish-Berhane, A. Roshak, D. Millington, Patricia A. Lorenzini, M. Thayu, R. Knoblauch, B. Cho   +33 more
semanticscholar   +1 more source

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Nature Communications, 2023
Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), potently and selectively inhibits EGFR-TKI-sensitizing and EGFR T790M resistance mutations.
J. Chmielecki, J. Gray, Ying Cheng, Y. Ohe, F. Imamura, B. Cho, Meng-Chih Lin, M. Majem, R. Shah, Y. Rukazenkov, A. Todd, A. Markovets, J. Barrett, R. Hartmaier, S. Ramalingam   +14 more
semanticscholar   +1 more source

Midazolam impedes lung carcinoma cell proliferation and migration via EGFR/MEK/ERK signaling pathway

Open Medicine, 2023
Non-small-cell lung cancer (NSCLC) is a dominating type of lung cancer with high morbidity and mortality. Midazolam has been reported to promote cell apoptosis in NSCLC, but the molecular mechanism of midazolam remains to be further explored.
Zhang Xiangchao, Han Zhe, Li Zhengjun, Wang Tao   +3 more
doaj   +1 more source

Epidermal growth factor receptor and STAT3 signal through KRAS have mutually opposite effects on CTEN

Journal of Biochemical and Clinical Genetics, 2021
Background: C-terminal tensin-like (CTEN) is a protein located at focal adhesions and has been reported to be an oncogene in the colon, breast, lung, and gastric cancer.
Saleh AlGhamdi, Salih Ibrahim, Kanwal Balloch, Darryl Jackson, Mohammad Ilyas   +4 more
doaj   +1 more source

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance

Journal of Hematology & Oncology, 2022
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR mutations.
Kai Fu, Fa Xie, Fang Wang, Liwu Fu
semanticscholar   +1 more source

A CRISPR Test for Rapidly and Sensitively Detecting Circulating EGFR Mutations

Diagnostics, 2020
The detection of EGFR mutations in circulating cell-free DNA can enable personalized therapy for cancer. The current techniques for detecting circulating EGFR mutations are expensive and time-consuming with moderate sensitivity.
Jen-Hui Tsou, Qixin Leng, Feng Jiang
doaj   +1 more source